Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Director of Actuarial Services, Government Programs||
|Regional Director, Southeastern Region - State Affairs||
America's Health Insurance Plans (AHIP)
|Counsel I – Clinical Contracts||
|Foster City, CA|
|Associate - Food and Drug||
Keller and Heckman LLP
|Vice President, Idaho Regional Director||